Validation of Treatment Strategies for Enterohaemorrhagic Escherichia Coli O104:H4 Induced Haemolytic Uraemic Syndrome: Case-control Study

Objective: To evaluate the effect of different treatment strategies on enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome.

Design: Multicentre retrospective case-control study.

Setting: 23 hospitals in northern Germany.

Participants: 298 adults with enterohaemorrhagic E coli induced haemolytic uraemic syndrome.

Main Outcome Measures: Dialysis, seizures, mechanical ventilation, abdominal surgery owing to perforation of the bowel or bowel necrosis, and death.

Results: 160 of the 298 patients (54%) temporarily required dialysis, with only three needing treatment long term. 37 patients (12%) had seizures, 54 (18%) required mechanical ventilation, and 12 (4%) died. No clear benefit was found from use of plasmapheresis or plasmapheresis with glucocorticoids. 67 of the patients were treated with eculizumab, a monoclonal antibody directed against the complement cascade. No short term benefit was detected that could be attributed to this treatment. 52 patients in one centre that used a strategy of aggressive treatment with combined antibiotics had fewer seizures (2% v 15%, P = 0.03), fewer deaths (0% v 5%, p = 0.029), required no abdominal surgery, and excreted E coli for a shorter duration.

Conclusions: Enterohaemorrhagic E coli induced haemolytic uraemic syndrome is a severe self limiting acute condition. Our findings question the benefit of eculizumab and of plasmapheresis with or without glucocorticoids. Patients with established haemolytic uraemic syndrome seemed to benefit from antibiotic treatment and this should be investigated in a controlled trial.

Citing Articles

Inhibition of tumour necrosis factor alpha by Etanercept attenuates Shiga toxin-induced brain pathology.

Christ R, Siemes D, Zhao S, Widera L, Spangenberg P, Lill J J Neuroinflammation. 2025; 22(1):33.

PMID: 39920757 PMC: 11804009. DOI: 10.1186/s12974-025-03356-z.

Complement-Mediated Hemolytic Uremic Syndrome Due to MCP/CD46 Mutation: A Case Report.

Abdeen A, Al-Nusair J, Samardali M, Alshal M, Al-Astal A, Khitan Z J Investig Med High Impact Case Rep. 2025; 13:23247096251316364.

PMID: 39871416 PMC: 11773514. DOI: 10.1177/23247096251316364.

IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement.

Duneton C, Kwon T, Dossier C, Baudouin V, Fila M, Mariani-Kurkdijan P Pediatr Nephrol. 2024; 40(2):431-440.

PMID: 39297957 DOI: 10.1007/s00467-024-06418-1.

Two cases of typical HUS in adults treated with an anti-C5 monoclonal antibody: a new perspective?.

Stambolliu E, Giannou P, Nomikou E, Aggelis G, Petras D J Nephrol. 2024; .

PMID: 39073701 DOI: 10.1007/s40620-024-02034-2.

Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy.

Sayk F, Hauswaldt S, Knobloch J, Rupp J, Nitschke M Front Public Health. 2024; 12:1364664.

PMID: 38699424 PMC: 11064650. DOI: 10.3389/fpubh.2024.1364664.

References

Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, Moller F . The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain. 2012; 135(Pt 6):1850-9. DOI: 10.1093/brain/aws090. View

Szczepiorkowski Z, Winters J, Bandarenko N, Kim H, Linenberger M, Marques M . Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010; 25(3):83-177. DOI: 10.1002/jca.20240. View

Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba H . Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009; 360(5):542-4. DOI: 10.1056/NEJMc0808527. View

Rahal E, Kazzi N, Kanbar A, Abdelnoor A, Matar G . Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents. 2010; 37(2):135-9. DOI: 10.1016/j.ijantimicag.2010.10.009. View

Wong C, Jelacic S, Habeeb R, Watkins S, Tarr P . The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000; 342(26):1930-6. PMC: 3659814. DOI: 10.1056/NEJM200006293422601. View

Mellmann A, Harmsen D, Cummings C, Zentz E, Leopold S, Rico A . Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One. 2011; 6(7):e22751. PMC: 3140518. DOI: 10.1371/journal.pone.0022751. View

Hillmen P, Young N, Schubert J, Brodsky R, Socie G, Muus P . The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006; 355(12):1233-43. DOI: 10.1056/NEJMoa061648. View

Tarr P, Gordon C, Chandler W . Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365(9464):1073-86. DOI: 10.1016/S0140-6736(05)71144-2. View

Cornick N, Jelacic S, Ciol M, Tarr P . Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome. J Infect Dis. 2002; 186(1):57-63. DOI: 10.1086/341295. View

10.

Ruggenenti P, Remuzzi G . A German outbreak of haemolytic uraemic syndrome. Lancet. 2011; 378(9796):1057-8. DOI: 10.1016/S0140-6736(11)61217-8. View

11.

Bell B, Goldoft M, Griffin P, Davis M, Gordon D, Tarr P . A multistate outbreak of Escherichia coli O157:H7-associated bloody diarrhea and hemolytic uremic syndrome from hamburgers. The Washington experience. JAMA. 1994; 272(17):1349-53. View

12.

Pennington H . Escherichia coli O157. Lancet. 2010; 376(9750):1428-35. DOI: 10.1016/S0140-6736(10)60963-4. View

13.

Ducker C, Dautel P, Wagner K, Przewozna J, Oehlerking S, Repenthin J . [Clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as in-patients]. Dtsch Med Wochenschr. 2011; 136(36):1770-6. DOI: 10.1055/s-0031-1286099. View

14.

Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P . Steroids in the hemolytic uremic syndrome. Pediatr Nephrol. 1998; 12(2):101-4. DOI: 10.1007/s004670050413. View

15.

Denamur E . The 2011 Shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticity. Clin Microbiol Infect. 2011; 17(8):1124-5. DOI: 10.1111/j.1469-0691.2011.03620.x. View

16.

Thurman J, Marians R, Emlen W, Wood S, Smith C, Akana H . Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009; 4(12):1920-4. PMC: 2798880. DOI: 10.2215/CJN.02730409. View

17.

Colic E, Dieperink H, Titlestad K, Tepel M . Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet. 2011; 378(9796):1089-93. DOI: 10.1016/S0140-6736(11)61145-8. View

18.

Stahl A, Sartz L, Karpman D . Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood. 2011; 117(20):5503-13. DOI: 10.1182/blood-2010-09-309161. View

19.

Zhang X, McDaniel A, Wolf L, Keusch G, Waldor M, Acheson D . Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis. 2000; 181(2):664-70. DOI: 10.1086/315239. View

20.

Kemper M . Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective. Pediatr Nephrol. 2011; 27(2):161-4. DOI: 10.1007/s00467-011-2067-7. View